Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib

MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs